×
Sign in
Menu
Home
Resources
Back To Top
×
Contact the Presenter
×
Add To Cart
×
Test
ESMO Virtual Congress 2020
Final Programme PDF
Advanced Search
14.09.2020
15.09.2020
17.09.2020
18.09.2020
19.09.2020
20.09.2020
21.09.2020
22.09.2020
23.09.2020
12.10.2020
13.10.2020
14.10.2020
15.10.2020
16.10.2020
17.10.2020
18.10.2020
ESMO Colloquium
Industry Satellite Symposium
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
23:00
00:00
Channel 1
13:00(1h 30m)
ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Channel: On-Demand
09:00(14h 59m)
Amgen (Europe) GmbH - New horizons in the era of precision medicine in lung cancer: KRAS and DLL3 as emerging treatment targets
09:00(14h 59m)
AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
09:00(14h 59m)
AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer
09:00(14h 59m)
AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
09:00(14h 59m)
AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
09:00(14h 59m)
Daiichi Sankyo -Antibody Drug Conjugates (ADCs): Advancements in the treatment of solid tumours
09:00(14h 59m)
F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
09:00(14h 59m)
F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
09:00(14h 59m)
GSK - Treatment options for women with advanced ovarian cancer: Evaluating the evidence
09:00(14h 59m)
GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
09:00(14h 59m)
Ipsen - What does the changing treatment landscape for aRCC mean for patient care: An expert discussion
09:00(14h 59m)
Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
09:00(14h 59m)
Merck - From complexity to clarity: Optimizing the mCRC continuum of care (Medical)
09:00(14h 59m)
Merck Pfizer Alliance - 2020: New decade, new treatment choices in GU cancer (Medical)
09:00(14h 59m)
MSD - Evolving treatment paradigms for head and neck squamous cell carcinoma (HNSCC)
09:00(14h 59m)
MSD - Redefining survival expectations in NSCLC
09:00(14h 59m)
Novartis - Pushing the boundaries: Expanding treatment options for patients with melanoma
09:00(14h 59m)
Novartis - Transforming treatment in HR+/HER2- advanced breast cancer
09:00(14h 59m)
Samsung Bioepis - Navigating the Optimized Oncology Treatment Options in Colorectal Cancer, Lung Cancer and Breast Cancer Through Multidisciplinary Discussions
09:00(14h 59m)
Sanofi Genzyme - Immune checkpoint blockade in non-melanoma skin cancer
09:00(14h 59m)
Seattle Genetics - Patient-focused look at tomorrow’s world in HER2+ metastatic breast cancer
09:00(14h 59m)
TouchIME - PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
×
Dialog
×
Sponsored Access
Access to the resources are offered to you by
ESMO Events